2nd Annual Multi-Functional Cell Therapies Summit

Memo

Cell therapies hold life-saving potential for patients and the race is on to develop best-in-class, living, 'thinking' drugs. Relapse rates and barriers to solid tumor efficacy mean the cell therapy industry must innovate, now more than ever. Due to its successful first edition, the Multi-Functional Cell Therapies Summit is returning for 2022 and will be uniting global leaders to discuss strategies to weaponize cell therapies with antigenic, engineered, and combination approaches to create sophisticated multi-functional systems. View the full event brochure here: https://ter.li/6o9ghc The 2nd Annual Multi-Functional Cell Therapies Summit remains the only cell-type agnostic, targeting focused meeting providing a platform for overcoming the challenges to weaponizing cell therapies against solid tumors such as: -Understanding and overcoming the immunosuppressive nature of the TME to inform future drug development-Exploiting multiple functions through innovative engineering and novel targeting approaches to produce "smarter" cell therapies with high efficacy and safety profiles-Synergizing analytical strategy with efficient and standardized manufacturing to overcome regulatory barriers preventing approval Join us as we bring together drug developers and innovators to tackle unique cell therapy development challenges creating obstacles for effective treatments for solid tumor patients. Register for your ticket here: https://ter.li/ntcd3z URLs:Tickets: https://go.evvnt.com/897138-2?pid=5569Brochure: https://go.evvnt.com/897138-3?pid=5569 Prices:Conference + Workshop Day | Drug Developer | Early Bird 1: USD 2196.0,Conference Only | Drug Developer | Early Bird 1: USD 1599.0,Conference + Workshop Day | Academic Price | Early Bird 1: USD 1846.0,Conference Only | Academic Price | Early Bird 1: USD 1399.0,Conference + Workshop Day | Solution Provider | Early Bird 1: USD 2796.0,Conference Only | Solution Provider | Early Bird 1: USD 1899.0 Speakers: Qi Cai Director of Cell Biology Kite Pharma, Tanja Obradovic Senior Scientific Director Takeda, Markus Vallaster Executive Medical Director AstraZeneca, Elena Peletskaya Director, Portfolio Technical Strategy Bristol Myers Squibb, Friedrich Graf Finckenstein M.D. Chief Medical Officer Iovance Biotherapeutics, Laurent Poirot CTO Cellectis, Peggy Sotiropoulou CSO T-knife Therapeutics, Hans-Peter Gerber CSO 3T Biosciences, Luis Borges Chief Scientific Officer Century Therapeutics, Blake Aftab Vice President, Head of Research Adicet Bio, Barbara Sennino Senior Director, Tumor Immunology PACT Pharma, Daniel Getts CEO Myeloid Therapeutics, Lawrence Lamb Chief Scientific Officer IN8 Bio, Chris Bond SVP Pre-Clinical and Translational Sciences Notch Therapeutics , Austin Bigley VP of Research and Development Indapta, Karrie Wong Director of Cell Therapy KSQ Therapeutics, Alexander Kamb Chief Scientific Officer A2 Biotherapeutics Inc., Marc van Dijk Chief Scientific Officer MiNK Therapeutics, Tamara Laskowski Project Director MD Anderson Cancer Centre, Paul Lammers President and CEO Triumvira Immunologics, John Rossi Senior Vice President Research CERo Research, Head of Translational, Alessandra Sullivan Principal Scientist Umoja Biopharma, Nicholas Boyd Chief Development Officer Cartherics, Daniel Abate-Daga Associate Professor H. Lee Moffitt Cancer Center and Research, Marcela Guzman Associate Director Senti Biosciences, Bertie MacArthur Researcher Beacon Therapies, John Maher Chief Scientific Officer Leucid Bio, Thomas Condamine Senior Director, Discovery and Translational Sciences Carisma, Brian Garrison Director of Research Senti Bio Date and Time: On Tuesday January 25, 2022 at 8:00 am (ends Thursday January 27, 2022 at 5:00 pm)